Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Wiener Klinische Wochenschrift|August 3, 2023
Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in AustriaLeila Ronceray, Michael Dworzak, Karin Dieckmann, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|September 5, 2022
Medial Prefrontal Cortex Activity to Reward Outcome Moderates the Association Between Victimization Due to Sexual Orientation and Depression in YouthKristen L Eckstrand, Jennifer S Silk, Melissa Nance, et al.
Journal of Medicinal Chemistry|January 10, 2017
Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo StudiesNiall Igoe, Elliott D Bayle, Oleg Fedorov, et al.
Cancers|February 5, 2021
Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94Stefan Fiedler, Inge M Ambros, Evgenia Glogova, et al.
Molecular Genetics and Metabolism|January 26, 2024
Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshopSarah C Grünert, Terry G J Derks, Helen Mundy, et al.
Journal of Neuroscience Research|May 4, 2011
Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophreniaMichael R Barnes, Julie Huxley-Jones, Peter R Maycox, et al.
Clinical Immunology (Orlando, Fla.)|November 27, 2019
Distinct molecular response patterns of activating STAT3 mutations associate with penetrance of lymphoproliferation and autoimmunitySabine Jägle, Maximilian Heeg, Sarah Grün, et al.
British Journal of Cancer|November 20, 2020
Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivityAdan Pinto-Fernandez, Mariolina Salio, Tom Partridge, et al.
JAMA Oncology|October 26, 2023
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled TrialAndreas Peyrl, Monika Chocholous, Magnus Sabel, et al.
Elife|October 12, 2021
USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinomaE Josue Ruiz, Adan Pinto-Fernandez, Andrew P Turnbull, et al.
Pageof 9